Non-profit drugmaker Civica Rx has said it will launch biosimilars of three big-selling insulin products in the US by 2024 to help diabetic patients struggling with the cost of the drugs.

The biggest stories of the day delivered to your inbox.

Get the best of the Pacific in your inbox!